Form 4: Krystal Biotech CEO and Spouse Execute Scheduled Stock Sales Under 10b5-1 Plans

Krystal Biotech's President and CEO, Krish S. Krishnan, and his spouse, Suma M. Krishnan, reported the sale of 14,127 shares of common stock totaling approximately $2.12 million through pre-arranged Rule 10b5-1 trading plans on July 9 and 10, 2025.

Summary

• Krish S. Krishnan, President and CEO, Director, and 10% Owner of Krystal Biotech, Inc. (KRYS), reported sales of common stock.
• On July 9, 2025, Krish S. Krishnan directly sold 200 shares of common stock at an average price of $150.07.
• On July 10, 2025, Krish S. Krishnan directly sold 6,627 shares at a weighted average price of $150.2184 and 300 shares at an average price of $151.3867.
• Following these direct transactions, Krish S. Krishnan beneficially owns 1,525,929 shares directly.
• Additionally, Krish S. Krishnan's spouse, Suma M. Krishnan, indirectly sold shares under her own Rule 10b5-1 plan.
• On July 9, 2025, 200 shares were sold indirectly by the spouse at a weighted average price of $150.139.
• On July 10, 2025, 6,500 shares were sold indirectly by the spouse at a weighted average price of $150.2252 and 300 shares at an average price of $151.3867.
• Following these indirect transactions, 1,456,711 shares are beneficially owned indirectly by the spouse.
• All reported sales by both Krish S. Krishnan and his spouse were executed pursuant to pre-arranged Rule 10b5-1 trading plans.
• The Reporting Person also indirectly beneficially owns 90,000 shares through the Krishnan Spousal Trust and 50,000 shares through the Krishnan Family Trust.

Sentiment

Score: 6

Explanation: While insider selling can be perceived negatively, the fact that these sales were conducted under pre-arranged Rule 10b5-1 plans mitigates much of the negative sentiment. Such plans indicate a scheduled, non-discretionary transaction rather than a reaction to new, negative information about the company. The sales represent a small portion of the total beneficial ownership.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a scheduled, non-discretionary transaction rather than a reaction to new, negative information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

The Rule 10b5-1 trading plans for Krish S. Krishnan and his spouse are scheduled to terminate on September 13, 2025, indicating that further pre-scheduled sales under these specific plans will cease after this date.

Management Comments

• The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025.
• The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Suma M. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025.
• The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Industry Context

This Form 4 filing reports routine insider stock sales under pre-arranged trading plans, which is a common practice for executives to diversify their holdings and manage liquidity without being accused of trading on material non-public information. It does not provide specific insights into broader industry trends or competitive landscape for Krystal Biotech.

Comparison to Industry Standards

• Insider selling under Rule 10b5-1 plans is a standard practice among executives in publicly traded companies across various industries, including biotechnology. This mechanism allows insiders to sell shares at pre-determined times or prices, providing an affirmative defense against insider trading allegations.
• For example, executives at companies like Moderna (MRNA) or Pfizer (PFE) frequently utilize 10b5-1 plans for their stock transactions, making these sales generally less indicative of management's immediate sentiment about the company's short-term prospects compared to unscheduled sales.
• The volume of shares sold (14,127 shares) represents a small fraction of the total beneficial ownership (over 3 million shares combined direct and indirect), which is typical for diversification purposes rather than a significant divestment.

Related Party Transactions

• Sales of common stock by Suma M. Krishnan, spouse of the Reporting Person, are reported as indirect beneficial ownership.
• Shares held by Krishnan Spousal Trust and Krishnan Family Trust are also reported as indirect beneficial ownership, with the Reporting Person and his spouse being joint beneficial owners of the Family Trust.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO and his spouse, even under a 10b5-1 plan, might lead to minor concerns about management's conviction, though the pre-scheduled nature typically alleviates significant alarm. It could also be seen as a routine diversification.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The Rule 10b5-1 trading plans for Krish S. Krishnan and Suma M. Krishnan are set to terminate on September 13, 2025.

Key Dates

Recommendation

Keywords

Krystal Biotech, KRYS, SEC Form 4, insider trading, stock sale, 10b5-1 plan, Krish S. Krishnan, common stock, beneficial ownership